Immunotherapy represents a paradigm shift in cancer treatment; checkpoint inhibitors targeting the PD-1/PD-L1 axis have been reported to provide promising clinical responses in patients with various types of cancer5,22. This evidence concerns the gene PDCD1 and cancer.